Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Chief Operating Officer | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cadrenal Therapeutics, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2036-10-08 | Direct | 150,000 |
Reported balance
After 2026-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 150,000 · Balance 150,000 F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 21:32 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001213900-26-109129 · ownership.xml · derivative · entry 1 Cole Jeffrey Scott · CIK 0001751100 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-10-08 F1 · shares: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. F1 · derivative.exercise_date: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:11 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006635 · ownership.xml · derivative · entry 1 Cole Jeffrey Scott · CIK 0001751100 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-22 F1 · security: Consists of options to purchase 25,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 17:21 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001213900-24-029930 · ownership.xml · derivative · entry 1 Cole Jeffrey Scott · CIK 0001751100 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-04-01 F1 · security: Consists of options to purchase 150,000 shares of common stock, which shall vest 1/4 on April 1, 2025 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. F1 · derivative.underlying_shares: Consists of options to purchase 150,000 shares of common stock, which shall vest 1/4 on April 1, 2025 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.